MA46436A - Compositions comprenant de la relaxine et leurs méthodes d'utilisation - Google Patents
Compositions comprenant de la relaxine et leurs méthodes d'utilisationInfo
- Publication number
- MA46436A MA46436A MA046436A MA46436A MA46436A MA 46436 A MA46436 A MA 46436A MA 046436 A MA046436 A MA 046436A MA 46436 A MA46436 A MA 46436A MA 46436 A MA46436 A MA 46436A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compositions including
- including relaxin
- relaxin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/005—Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662405795P | 2016-10-07 | 2016-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46436A true MA46436A (fr) | 2019-08-14 |
Family
ID=60186382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046436A MA46436A (fr) | 2016-10-07 | 2017-10-09 | Compositions comprenant de la relaxine et leurs méthodes d'utilisation |
Country Status (7)
Country | Link |
---|---|
US (1) | US11723957B2 (fr) |
EP (2) | EP3522911B1 (fr) |
AU (1) | AU2017339536A1 (fr) |
CA (1) | CA3078452A1 (fr) |
DK (1) | DK3522911T3 (fr) |
MA (1) | MA46436A (fr) |
WO (1) | WO2018068047A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
EP4153214A1 (fr) | 2020-05-22 | 2023-03-29 | Trustees of Boston University | Méthodes et compositions pour le traitement d'une maladie fibrotique |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2857684B2 (ja) | 1989-05-04 | 1999-02-17 | ジェネンテク,インコーポレイテッド | ヒトリラキシンの単離のための方法および組成物 |
US6251863B1 (en) * | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
ITFI20030328A1 (it) * | 2003-12-24 | 2005-06-25 | Mario Bigazzi | Uso della relaxina come adiuvante nella differenziazione |
MX346786B (es) * | 2010-08-17 | 2017-03-31 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos. |
US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
WO2015067791A1 (fr) * | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Promédicaments à bae de relaxine |
US11161891B2 (en) * | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
-
2017
- 2017-10-09 DK DK17791235.9T patent/DK3522911T3/da active
- 2017-10-09 MA MA046436A patent/MA46436A/fr unknown
- 2017-10-09 EP EP17791235.9A patent/EP3522911B1/fr active Active
- 2017-10-09 WO PCT/US2017/055799 patent/WO2018068047A1/fr unknown
- 2017-10-09 AU AU2017339536A patent/AU2017339536A1/en active Pending
- 2017-10-09 CA CA3078452A patent/CA3078452A1/fr active Pending
- 2017-10-09 US US16/339,659 patent/US11723957B2/en active Active
- 2017-10-09 EP EP21212781.5A patent/EP4056196A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3522911A1 (fr) | 2019-08-14 |
WO2018068047A1 (fr) | 2018-04-12 |
WO2018068047A8 (fr) | 2019-03-21 |
EP4056196A1 (fr) | 2022-09-14 |
EP3522911B1 (fr) | 2021-12-08 |
DK3522911T3 (da) | 2022-03-07 |
US20190282665A1 (en) | 2019-09-19 |
CA3078452A1 (fr) | 2018-04-12 |
US11723957B2 (en) | 2023-08-15 |
AU2017339536A1 (en) | 2019-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA49288A (fr) | Reactifs particulaires oligomères et leurs méthodes d'utilisation | |
MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation |